Recent Posts
- ENTREVESTOR: IMV Inc. entering a crucial phase in late 2019
- Mallinckrodt Agrees to Sell BioVectra Inc. to H.I.G. Capital for $250 Million
- IMV Announces Research Collaboration with The Wistar Institute to Develop New Targeted Immunotherapy Against the Common BRAF Cancer Mutation
- ACOA NEWS RELEASE: Panag Pharma providing effective, non-addictive plant-based pain management
- Entrevestor: Motryx Wins $100K Women’s Fund Grant